Roddy E, Zhang W, Doherty M. - The changing epidemiology of gout. Nat Clin Pract Rheumatol, 2007, 3, 443-449.
Zhu Y, Pandya BJ, Choi HK. - Prevalence of gout and hyperuricemia in the US general population : the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum, 2011, 63, 3136-3141.
Burns CM, Wortmann RL. - Gout therapeutics : new drugs for an old disease. Lancet, 2011, 377, 165-177.
Wallace SL, Robinson H, Masi AT, et al. - Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum, 1977, 20, 895-900.
Zhang W, Doherty M, Pascual E, et al. - EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2006, 65, 1301-1311. (Pubitemid 44641591)
Dubost JJ, Mathieu S, Soubrier M. - Traitement de la goutte. Rev Med Interne, 2011, 32, 751-757.
Zhang W, Doherty M, Bardin T, et al. - EULAR evidence based recommendations for gout. Part II : management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2006, 65, 1312-1324. (Pubitemid 44620440)
Kramer HJ, Choi HK, Atkinson K, et al. - The association between gout and nephrolithiasis in men : the health professionals' follow-up study. Kidney Int, 2003, 64, 1022-1026. (Pubitemid 37013838)
Choi HK, Atkinson K, Karlson EW, et al. - Alcohol intake and risk of incident gout in men : a prospective study. Lancet, 2004, 363, 1277-1281. (Pubitemid 38496489)
Choi HK, Atkinson K, Karlson EW, et al. - Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med, 2004, 350, 1093-1103. (Pubitemid 38298989)
Bull PW, Scott JT. - Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol, 1989, 16, 1246-1248. (Pubitemid 19260116)
Campion EW, Glynn RJ, DeLabry LO. - Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med, 1987, 82, 421-426.
Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. - Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis, 1998, 57, 545- 549.
Perez-Ruiz F, Calabozo M, Pijoan JI, et al. - Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum, 2002, 47, 356-360. (Pubitemid 34856121)
Shoji A, Yamanaka H, Kamatani N. - A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum, 2004, 51, 321-325. (Pubitemid 38725128)
Li-Yu J, Clayburne G, Sieck M, et al. - Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol, 2001, 28, 577-580. (Pubitemid 32202663)
McCarthy GM, Barthelemy CR, Veum JA, et al. - Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum, 1991, 34, 1489-1494.
Jordan KM, Cameron JS, Snaith M, et al. - British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford), 2007, 46, 1372-1374.
Becker MA, Schumacher HR, Wortmann RL, et al. - Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 2005, 353, 2450-2461. (Pubitemid 41781828)
Dalbeth N, Kumar S, Stamp L, et al. - Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol, 2006, 33, 1646-1650. (Pubitemid 44168841)
Schumacher HR, Becker MA, Wortmann RL, et al. - Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum, 2008, 59, 1540-1548.
Rodnan GP, Robin JA, Tolchin SF, et al. - Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA, 1975, 231, 1143-1147.
Rundles RW, Metz EN, Silberman HR. - Allopurinol in the treatment of gout. Ann Intern Med, 1966, 64, 229-258.
Arellano F, Sacristan JA. - Allopurinol hypersensitivity syndrome : a review. Ann Pharmacother, 1993, 27, 337-343.
Mayer MD, Khosravan R, Vernillet L, et al. - Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther, 2005, 12, 22-34. (Pubitemid 40516043)
Khosravan R, Grabowski BA, Mayer MD, et al. - The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol, 2006, 46, 88-102. (Pubitemid 43021717)
Becker MA, Schumacher HR, Wortmann RL, et al. - Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase : a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum, 2005, 52, 916-923. (Pubitemid 40372228)
Becker MA, Schumacher HR, Espinoza LR, et al. - The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther, 2010, 12, R63.
Yamanaka H, Togashi R, Hakoda M, et al. - Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol, 1998, 431, 13-18. (Pubitemid 28236731)
Schumacher HR, Becker MA, Lloyd E, et al. - Febuxostat in the treatment of gout : 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford), 2009, 48, 188-194.
Becker MA, Schumacher HR, MacDonald PA, et al. - Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol, 2009, 36, 1273-1282.
Sarawate CA, Brewer KK, Yang W, et al. - Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc, 2006, 81, 925-934. (Pubitemid 43993484)
Delanaye P, Cavalier E, Mariat C, et al. - Détection et estimation du niveau de la maladie rénale chronique. Rev Med Liège, 2009, 64, 73-78.
Borstad GC, Bryant LR, Abel MP, et al. - Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol, 2004, 31, 2429-2432. (Pubitemid 39610535)
Stamp LK, O'Donnell JL, Zhang M, et al. - Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum, 2011, 63, 412-421.
Reinders MK, Haagsma C, Jansen TL, et al. - A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis, 2009, 68, 892-897.
